Based on a small sampling, the response is mixed. StemLifeLine of San Carlos says it is not planning to apply because of requirements that the state receive a payback on any revenues that may result, according to reporter Steve Johnson.
Advanced Cell Technology of Los Angeles, on the other hand, is interested. It moved its headquarters to California last year because of the possibility of securing funding from CIRM.
Geron of Menlo Park says it is not applying because its technology has advanced beyond the levels funded by the institute.
WaferGen Bio-systems of Fremont is considering applying but is concerned about the revenue sharing.
StemCyte of Arcadia said that it has filed a letter of intent to apply for a disease-team planning grant. The deadline for those letters came Thursday. CIRM , however, that it is not sure that it will be able to supply figures today on the number of applications, including those from business.
CIRM Chairman Robert Klein said,
"We will try to work with industry to find how we can further the interests of California patients and the biotech sector."